Professor David Ludwig

"Dr David Ludwig - Nutrition Seminar"

Dr David Ludwig's lecture on the Carbohydrate-Insulin Model of Obesity for the Nutrition Seminar Series, Harvard School of Public Health.

OFH: Dr Ludwig is the experts, expert. This lecture is very dense and you might need to take notes.

Comment from a YouTube customer: I find the clarity of this presentation to be very high, even though my PhD is not in nutrition at all. I look forward to hearing about future research. It would also be useful if Dr. Ludwig etc could assemble a list citing 5-10 recent papers in highly respected technical journals that I could suggest to my own doctors to read from Primary sources to understand these concepts. My doctors are not going to be open to ideas that a non-doctor such as myself suggested based on YouTube videos or "popular" books such as "Always Hungry".

Dr. David Ludwig is an endocrinologist and researcher at Boston Children’s Hospital. He’s a Professor of Pediatrics at Harvard Medical School and Professor of Nutrition at Harvard School of Public Health.

For more than 25 years, Dr. Ludwig has studied the effects of dietary composition on metabolism, body weight and risk for chronic disease – with a special focus on low-glycemic index, low-carbohydrate and ketogenic diets.

Described as an “obesity warrior” by Time Magazine, Dr. Ludwig has fought for fundamental policy changes to improve the food environment.

He has authored more than 200 scientific articles and presently serves as an editor at The American Journal of Clinical Nutrition.

Harvard's Dr. David Ludwig addresses whether GLP-1 weight loss drugs like semaglutide, Wegovy & Ozempic should replace keto and low-carb diets for obesity, even in children. Or can low-carb diets complement drug treatments to reduce costs and long-term health risks and provide a path to life-long metabolic health?

Dr. Ludwig's new paper on the social justice implications of this issue is co-authored by Dr. Jens J. Holst, who has been credited with discovering the hormone GLP-1.

The GLP-1 medications semaglutide, Wegovy & Ozempic have taken the weight loss community by storm. They are even recommended for children and adolescents with obesity. But what are the long-term consequences of such widespread use, and why has the medical community seemingly abandoned dietary changes and behavioral support for medications and surgery? And what about the impact on long-term metabolic health and on questions of social justice?